Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?
These results do not clearly support routine N-desmethyl monitoring since it does not provide additional information to imatinib data.
Authors
- Aurélie Brice
- Étienne Chatelut (ORCID: https://orcid.org/0000-0002-7740-9096)
- Sabrina Marsili
- Fabienne Thomas (ORCID: https://orcid.org/0000-0001-9886-412X)
- Thierry Lafont
- Malika Yakoubi
- Ben Allal (ORCID: https://orcid.org/0000-0002-4207-2219)
- Mélanie White‐Koning (ORCID: https://orcid.org/0000-0001-5072-5489)
- Clara Eschalier
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Institut Claudius Regaud (FR)
Publication Details
- Journal
- Chemotherapy
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1159/000541936
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00